International Conference on Reproduction and Fertility October 18-19, 2018 Abu Dhabi, UAE
October 18-19, 2018 Abu Dhabi, UAE
Preeclampsia is a disease mainly occurs in pregnant ladies. This disease characterized by high blood pressure and it also damages the other organs of the body. This Preeclampsia disease usually starts after 20-25 weeks of pregnancy in a woman whose blood pressure is in normal stage. Even for simple complications in blood pressure may be a sign of Preeclampsia. Left untreated, preeclampsia can lead to serious — even fatal — complications for both you and your baby. If you have preeclampsia, the only cure is delivery of your baby. If you're diagnosed with preeclampsia too early in your pregnancy to deliver your baby, you and your doctor face a challenging task. Your baby needs more time to mature, but you need to avoid putting yourself or your baby at risk of serious complications.
Sometimes Preeclampsia may develop without any symptoms. High blood pressure may develop slowly, but more commonly it has a sudden onset. Monitoring your blood.
Treatment: The main cure for preeclampsia is only delivery. You're at increased risk of seizures, placental abruption, stroke and possibly severe bleeding until your blood pressure decreases. Of course, if it's too early in your pregnancy, delivery may not be the best thing for your baby. If you're diagnosed with preeclampsia, your doctor will let you know how often you'll need to come in for prenatal visits — likely more frequently than what's typically recommended for pregnancy. You'll also need more-frequent blood tests, ultrasounds and nonstress tests than would be expected in an uncomplicated pregnancy. Possible treatment for preeclampsia may include: Medications to lower blood pressure, Corticosteroids, Anticonvulsant medications
Statistics: In United Kingdom, the analysis is from 24 randomised controlled trials, evaluating antiplatelet agents, for the prevention of pre-eclampsia in pregnancy. We performed two-stage and one-stage IPD meta-analyses to estimate overall treatment effect and to explore potential treatment interactions whereby particular types of women and their babies might benefit differentially from receiving antiplatelets. Two-stage and one-stage approaches gave similar results, showing a benefit of using anti-platelets (Relative risk 0.90, 95% CI 0.84 to 0.97). Neither approach suggested that any particular type of women benefited more or less from antiplatelets. There were no material differences in results between different types of one-stage model.